logo-loader
viewMotif Bio PLC

Motif Bio's Graham Lumsden updates on FDA discussions and iclaprim potential

Motif Bio PLC's (LON:MTFB) Graham Lumsden chats to Proactive London's Andrew Scott after a meeting earlier this month with Food and Drug Administration officials to chart the next steps to get US regulators to approve their antibiotic iclaprim.

Feedback from that meeting is expected in early June.

Motif's acknowledged additional data will likely be required to address the agency’s concern about a risk of liver toxicity, although it will wait to hear what the FDA has to say before deciding the size and scope of any potential study.

Quick facts: Motif Bio PLC

Price: 0.05 GBX

AIM:MTFB
Market: AIM
Market Cap: £242.67 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Power Metal Resources 'pushing ahead with key projects' and in strong...

Power Metal Resources Plc's (LON:POW) Paul Johnson tells Proactive London's Andrew Scott they're in an advantageous financial position to deal with the current uncertainty around the coronavirus outbreak. He says they're conducting business diligently, safeguarding existing business...

1 day, 21 hours ago

2 min read